MedNet is proud to announce its inclusion on the INC 5000 list of fastest growing private companies for the second straight year.
MedNet Included in INC 5000 List
MedNet is proud to announce its inclusion on the INC 5000 list of fastest growing private companies for the second straight year. "We're both proud of our results and humbled by our good fortune and the dedication of our staff," said Rob Robertson President & CEO, "It appears our long term strategy of planned growth is bearing fruit. Ranking at number 36 in the Minneapolis-St Paul-Bloomingtoon-MN-WI region as a whole is very gratifying".
MedNet, a leading provider of eClinical Solutions, is headquatered in Minneapolis Minnesota, and counts Genentech, Teva Pharmaceuticals, AstraZeneca, ImClone, Medtronic and many others amongst its customer list for Studies of all phases conducted in over 40 countries. MedNet's corporate website is www.mednetstudy.com
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.